TIDMN4P

RNS Number : 2412Q

N4 Pharma PLC

25 February 2021

25 February 2021

N4 Pharma plc

("N4 Pharma" or the "Company")

Notice of Annual General Meeting

and

Posting of Annual Report and Accounts

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces that the Company's audited accounts for the year ended 31 December 2020, together with the notice of Annual General Meeting ("AGM"), are now available on the Company's website www.n4pharma.com and will be posted to shareholders today.

The AGM will be held at 10.00am on 24 March 2021. In line with current Covid-19 restrictions and in line with the Company's Articles of Association, this year's AGM will be a virtual meeting, full details of which are contained in the notice convening the AGM.

Enquiries:

 
 N4 Pharma plc 
 Nigel Theobald, CEO                            Via IFC Advisory 
 Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP                 Tel: +44(0)20 3470 
                                                 0470 
 Nominated Adviser and Joint Broker 
 Matthew Johnson/Caroline Rowe (Corporate 
  Finance) 
 Vadim Alexandre/Rob Rees (Corporate Broking) 
 
 Turner Pope Investments (TPI) Limited          Tel: +44(0)20 3657 
                                                 0050 
 Joint Broker 
 Andy Thacker/Zoe Alexander 
 
 IFC Advisory Ltd                               Tel: +44(0)20 3934 
  Financial PR                                   6630 
  Graham Herring 
  Zach Cohen 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACSSESFILEFSESE

(END) Dow Jones Newswires

February 25, 2021 02:00 ET (07:00 GMT)